CME Presentations
MDS
Presentations
Perspectives on the Promise of Novel Agents for the Treatment of Newly Diagnosed Intermediate/High-Risk MDS
Speakers: Naval Daver, MD, Associate ProfessorGuillermo Garcia-Manero, MD, Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, Department of Leukemia Duration: 60 minutes
Presented on: June 3, 2022
Speakers
Naval Daver, MD
Naval Daver, MD
Associate Professor
Naval Daver, MD, is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He is a clinical investigator with a focus on molecular and immune therapies in AML and myeloid disease and is principal investigator on over 25 ongoing institutional, national, and international clinical trials in these diseases. Dr. Daver is interested in developing monoclonal and bispecific antibodies and T-cell based approaches as well as combinations of targeted and apoptotic therapies in AML. He’s published over 400 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals and societies. In addition, Dr. Daver serves as Chair on numerous national and international meetings and educational platforms.Guillermo Garcia-Manero, MD
Guillermo Garcia-Manero, MD
Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, Department of Leukemia
Guillermo Garcia-Manero, MD, is the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research in the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC). He also serves as the Chief of the Section of Myelodysplastic Syndromes and Vice Chairman of the Department of Leukemia at UT MDACC. Moreover, he serves as Leader of the MDS/AML Moon Shot Program and Program Director of the Leukemia Fellowship Program at MD Anderson Cancer Center. Dr. Garcia-Manero’s research focuses on understanding the cellular and molecular biology of MDS and AML with an aim to improve therapeutic options for patients with these disorders. He has co- authored over 800 manuscripts. Currently, he is PI or Co-PI on over 30 active clinical trials focusing on AML and MDS.
CME Information
Strategies to Address Real-World Challenges in High-Risk Myelodysplastic SyndromeJointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.ACKNOWLEDGEMENT
This program has been supported by an independent educational grant from Gilead Sciences, Inc.DATE OF RELEASE/EXPIRATION
Thursday, April 6, 2023 from 12:30-1:30pm ET.TARGET AUDIENCE
The educational design of this activity addresses the needs of hematologic oncologists, hematologists, medical oncologists, oncology advanced practice providers (NPs and PAs), oncology nurses, pharmacists, and other clinicians involved in the management of patients with myelodysplastic syndrome (MDS).STATEMENT OF NEED/PROGRAM OVERVIEW
While approved chemotherapies and allogeneic stem-cell transplant have shown some success in the treatment of myelodysplastic syndrome (MDS), patients can still relapse or become refractory to treatment. Based on their risk stratification, patients with MDS need to receive the most suitable and effective therapy upfront. Clinical trials on immunotherapies for MDS are ongoing and agents with novel mechanisms are showing promising results.
Join a panel of expert hematologists and oncologists to review the team- and system-based gaps that prevent timely integration of new therapies for MDS. Panelists will share strategies to overcome barriers to the use of new advances in care and to create personalized treatment plans for patients with high-risk MDS based on their needs and preferences. Clinicians will learn how to select the right patients for novel therapies, whether through participation in clinical trials or in preparation of anticipated approvals.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Discuss the rationale for and mechanisms of action of novel immunotherapies for high-risk MDS
- Evaluate efficacy and safety profiles of emerging immunotherapies for high-risk MDS
- Outline strategies to individualize treatment plans for patients with high-risk MDS and align care with clinical guidelines
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PHYSICIAN CONTINUING EDUCATION
PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Name of Faculty or Presenter Reported Financial Relationship Naval Daver, MD
Associate Professor
Director, Leukemia Research Alliance Program
Department of Leukemia
MD Anderson Cancer CenterConsultant, Advisor, Speaker: AbbVie; Agios; Amgen; Arog; Astellas; Bristol-Meyers Squibb; Celgene; Daichii-Sankyo; Gilead; ImmunoGen; Jazz; Novartis; Pfizer; Servier; Servier; Shattuck Labs; Syndax; and Trillium.
Executive Role: Hanmi Pharmaceutical
Researcher: AbbVie; Amgen; Astellas; Bristol-Meyers Squibb; Daichii-Sankyo; FATE Therapeutics; Genentech; Gilead; Glycomimetics; ImmunoGen; Novimmune; Pfizer; Servier; Trillium; and Trovagene.David Sallman, MD
Assistant Member
Myeloid Malignancies Section Head, Malignant Hematology
Moffitt Cancer CenterConsultant, Advisor, Speaker: AbbVie; Affimed Gmbh; Avencell; Bluebird Bio; Bristol Myers Squibb; Gilead; Incyte; Intellia; Intellisphere, LLC; Jasper Therapeutics; Kite; Molecular Partners AG; Novartis; PGEN Therapeutics, Inc.; Servier; Shattack Labs; Syndax; Takeda; and Zentails.
Researcher: Aprea and Jazz
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.Perspectives on the Promise of Novel Agents for the Treatment of Newly Diagnosed Intermediate/High-Risk MDSThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Aplastic Anemia and MDS International Foundation (AAMDSIF).ACKNOWLEDGEMENT
This activity is supported by an educational grant from Gilead Sciences, Inc.DATE OF RELEASE/EXPIRATION
This activity was released on June 3, 2022 and is valid for 12 months. Requests for credit must be made no later than June 3, 2023.TARGET AUDIENCE
The educational design of this activity addresses the needs of hematologic oncologists, hematologists, medical oncologists, BMT specialists, NPs, PAs, oncology nurses, and other clinicians involved in the management of patients with MDS.STATEMENT OF NEED/PROGRAM OVERVIEW
While current therapies are inadequate for many patients with myelodysplastic syndromes (MDS), emerging therapies with different mechanisms of action are poised to provide more treatment options for newly diagnosed MDS and allow clinicians to treat with more certainty.
Join Dr. Naval Daver and Dr. Guillermo Garcia-Manero from MD Anderson Cancer Center to discuss current treatment options and unmet needs for different patient populations with MDS. The expert panel will further explore emerging targeted and combination therapies, including rationale for use, novel mechanisms of action, and the latest clinical data. As an issue of great importance, the evidence on disparities in clinical trials will be reviewed and strategies shared to educate patients on the clinical-trial process and its benefits, while encouraging enrollment when appropriate. Patient interviews will ensure the education remains patient-focused by providing their experiences with treatment and the clinical decision-making process.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Discuss the rationale for and mechanisms of action of novel agents under investigation for newly diagnosed MDS
- Evaluate efficacy and safety data from latest clinical trials on emerging novel agents for newly diagnosed MDS
- Recognize disparities in clinical trials and implement methods to reduce barriers by counseling eligible patients to participate in clinical trials
- Identify patient-centered approaches to MDS care via real-world patient accounts
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians..PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer CenterNothing to disclose Naval Daver, MD
Associate Professor
The University of Texas MD Anderson Cancer CenterConsulting Fee (e.g., Advisory Board): AbbVie, Agios, Amgen, Arog, Astellas, Bristol-Meyers Squibb, Celgene, Daichii-Sankyo, Genentech, Gilead, ImmunoGen, Jazz, Novartis, Pfizer, Servier Shattuck Labs, Syndax, Trillium
Contracted Research: AbbVie, Amgen, Astellas, Bristol-Meyers Squibb, Daiichi-Sankyo, FATE Therapeutics, Genentech, Gilead, Glycomimetics, Hanmi, ImmunoGen, Novimmune, Pfizer, Servier, Trillium, Trovagene
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner Reported Financial Relationship Rhys Williams, MSN, FNP-C, RN Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Jaimee Harris-Gold Nothing to disclose Tariqa Ackbarali Nothing to disclose Dan Stowell – Patient Participant Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive.com at 877-394-1306 or at Support@OMedLive.com.